PMID- 24656091
OWN - NLM
STAT- MEDLINE
DCOM- 20140512
LR  - 20141120
IS  - 1532-8392 (Electronic)
IS  - 0046-8177 (Linking)
VI  - 45
IP  - 4
DP  - 2014 Apr
TI  - HER2 amplification and overexpression are significantly correlated in mucinous 
      epithelial ovarian cancer.
PG  - 810-6
LID - S0046-8177(13)00523-6 [pii]
LID - 10.1016/j.humpath.2013.11.016 [doi]
AB  - HER2 gene amplification and protein over-expression are important factors in 
      predicting clinical sensitivity to anti-HER2 therapies in breast, gastric or 
      gastroesophageal junction cancer patients. The aim of this study was to evaluate 
      the correlation between HER2 gene copy numbers and HER2 protein expressions in 
      mucinous epithelial ovarian cancer (EOC). Of the 49 tissue microarray samples of 
      mucinous EOC, we applied 2010 ToGA trial (Trastuzumab for Gastric Cancer) 
      surgical specimen scoring criteria to analyze the HER2 protein expression by an 
      immunohistochemistry (IHC) test with Dako (Carpenteria, CA), c-erb-B2 antibody, 
      and the HER2 gene amplification by the fluorescence in situ hybridization (FISH) 
      test with Abbott/Vysis PathVysion HER2 DNA Probe Kit (Abbott Molecular Inc., Des 
      Plaines, IA). We achieved a high overall concordance of 97.56% between 
      nonequivocal HER2 results by IHC and FISH tests. In addition, HER2 gene copies 
      before chromosome-17 correction increased significantly in a stepwise order 
      through the negative, equivocal and positive IHC result categories (P<.001), as 
      did the HER2 gene copies after chromosome-17 correction (P<.001). On the other 
      hand, HER2 IHC results correlated significantly with both 
      chromosome-17-uncorrected HER2 gene copy numbers (rho=0.630, P<.001) and 
      chromosome-17 corrected HER2 gene copy numbers (rho=0.558, P<.001). We concluded 
      that both chromosome-17 corrected and uncorrected HER2 gene copies correlated 
      significantly with HER2 IHC results. Tests for the HER2 gene copies per tumor 
      cell either before or after correction of chromosome-17 can be applied as a 
      potentially valuable tool to analyze the HER2 status in mucinous EOC.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Chao, Wan-Ru
AU  - Chao WR
AD  - Institute of Medicine, Chung-Shan Medical University, Taichung, Taiwan; 
      Department of Pathology, Chung-Shan Medical University and Chung Shan Medical 
      University Hospital, Taichung, Taiwan.
FAU - Lee, Ming-Yung
AU  - Lee MY
AD  - Department of Statistics and Informatics Science, Providence University, 
      Taichung, Taiwan.
FAU - Lin, Wea-Long
AU  - Lin WL
AD  - Department of Pathology, Chung-Shan Medical University and Chung Shan Medical 
      University Hospital, Taichung, Taiwan.
FAU - Chen, Chi-Kuan
AU  - Chen CK
AD  - Department of Pathology, Mackay Memorial Hospital, Taipei, Taiwan.
FAU - Lin, Jau-Chen
AU  - Lin JC
AD  - Department of Respiratory Therapy, Fu-Jen Catholic University, Taipei, Taiwan.
FAU - Koo, Chiew-Loon
AU  - Koo CL
AD  - Institute of Medicine, Chung-Shan Medical University, Taichung, Taiwan; 
      Department of Pathology, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan.
FAU - Sheu, Gwo-Tarng
AU  - Sheu GT
AD  - Institute of Medicine, Chung-Shan Medical University, Taichung, Taiwan.
FAU - Han, Chih-Ping
AU  - Han CP
AD  - Department of Obstetrics and Gynecology, School of Medicine, Chung-Shan Medical 
      University and Chung-Shan Medical University Hospital, Taichung, Taiwan; 
      Department of Pathology, School of Medicine, Chung-Shan Medical University and 
      Chung-Shan Medical University Hospital, Taichung, Taiwan.. Electronic address: 
      hanhaly@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131212
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenocarcinoma, Mucinous/*genetics/metabolism
MH  - Chromosomes, Human, Pair 17/genetics
MH  - Female
MH  - *Gene Amplification
MH  - Gene Dosage
MH  - Gene Expression Profiling/*methods
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Ovarian Neoplasms/*genetics/metabolism
MH  - Receptor, ErbB-2/*biosynthesis/genetics
MH  - Tissue Array Analysis
OTO - NOTNLM
OT  - HER2
OT  - Mucinous epithelial ovarian cancer
OT  - Polysomy-17
EDAT- 2014/03/25 06:00
MHDA- 2014/05/13 06:00
CRDT- 2014/03/25 06:00
PHST- 2013/09/10 00:00 [received]
PHST- 2013/11/24 00:00 [revised]
PHST- 2013/11/27 00:00 [accepted]
PHST- 2014/03/25 06:00 [entrez]
PHST- 2014/03/25 06:00 [pubmed]
PHST- 2014/05/13 06:00 [medline]
AID - S0046-8177(13)00523-6 [pii]
AID - 10.1016/j.humpath.2013.11.016 [doi]
PST - ppublish
SO  - Hum Pathol. 2014 Apr;45(4):810-6. doi: 10.1016/j.humpath.2013.11.016. Epub 2013 
      Dec 12.